Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study.


Journal

Clinical and translational gastroenterology
ISSN: 2155-384X
Titre abrégé: Clin Transl Gastroenterol
Pays: United States
ID NLM: 101532142

Informations de publication

Date de publication:
12 2020
Historique:
entrez: 29 1 2021
pubmed: 30 1 2021
medline: 16 7 2021
Statut: ppublish

Résumé

A recent study in mice points to the gut-derived hormone glucagon-like peptide 2 (GLP-2) as an important regulator of gallbladder motility inducing gallbladder relaxation and refilling. In this study, we evaluated the effect of exogenous GLP-2 on postprandial gallbladder motility in healthy men. In a randomized, double-blinded, placebo-controlled, crossover study, we evaluated the effect of 4-hour intravenous infusions of high-dose GLP-2 (10 pmol × kg × min), low-dose GLP-2 (1 pmol × kg × min), and placebo (saline) on postprandial gallbladder motility. A 300-kcal liquid-mixed meal (added 1.5 g of acetaminophen for indirect measurement of gastric emptying) was served 30 minutes after start of intravenous infusions. Gallbladder volume was assessed by ultrasonography. Fifteen healthy men, age 24.3 (22.4-26.1) years (mean [95% confidence interval]) and body mass index 22.5 (21.7-23.4) kg × m, were included. Basal plasma GLP-2 concentration was 14 (11-17) pmol/L. During low-dose and high-dose GLP-2 infusions, steady-state postprandial plasma GLP-2 concentrations amounted to 201 (188-214) and 2,658 (2,443-2,873) pmol/L, respectively, compared with maximum postprandial plasma GLP-2 concentration of 34 (25-44) pmol/L during placebo. Gallbladder emptying (assessed as baseline-subtracted area under the curve for gallbladder volume) was reduced by low-dose GLP-2 (-0.8 [0.7-1.9] L × min, P < 0.0001) and nearly abolished by high-dose GLP-2 (1.3 [-1.7 to 0.01] L × min, P = 0.029) compared to placebo (-2.0 [-2.8 to -1.1] L × min). Compared to placebo, gastric emptying was reduced by high-dose GLP-2 (P = 0.0060 and 0.019), whereas low-dose GLP-2 did not affect gastric emptying (P = 0.13 and 0.85). Exogenous GLP-2 exerts a dose-dependent inhibitory effect on postprandial gallbladder emptying in healthy men.

Identifiants

pubmed: 33512799
doi: 10.14309/ctg.0000000000000257
pii: 01720094-202012000-00007
pmc: PMC7710225
doi:

Substances chimiques

Glucagon-Like Peptide 2 0

Types de publication

Clinical Trial, Phase I Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e00257

Références

Obes Surg. 2012 Jul;22(7):1084-96
pubmed: 22359255
Eur J Endocrinol. 2014 Oct;171(4):407-19
pubmed: 24986531
Diabetes Care. 2013 May;36(5):1396-405
pubmed: 23613599
J Clin Invest. 1991 Feb;87(2):415-23
pubmed: 1991827
Mol Endocrinol. 2011 Jun;25(6):1066-71
pubmed: 21454404
World J Gastroenterol. 2018 Nov 21;24(43):4870-4879
pubmed: 30487697
Regul Pept. 2010 Jan 8;159(1-3):67-71
pubmed: 19900491
Diabetologia. 2007 Oct;50(10):2135-42
pubmed: 17676310
Annu Rev Physiol. 2014;76:561-83
pubmed: 24161075
Bone. 2009 Nov;45(5):833-42
pubmed: 19631303
Curr Gastroenterol Rep. 2004 Apr;6(2):151-62
pubmed: 15191695
J Clin Endocrinol Metab. 2000 Aug;85(8):2884-8
pubmed: 10946898
Oncotarget. 2015 Aug 21;6(24):20661-71
pubmed: 25970782
Acta Radiol. 1990 Nov;31(6):591-6
pubmed: 2278784
Clin Transl Gastroenterol. 2016 Feb 04;7:e142
pubmed: 26844839
Gut. 1996 Nov;39(5):661-7
pubmed: 9026479
Lab Invest. 2015 Feb;95(2):124-31
pubmed: 25502177
Gut. 2005 Sep;54(9):1224-31
pubmed: 16099790
Curr Opin Endocrinol Diabetes Obes. 2015 Feb;22(1):14-20
pubmed: 25485516
J Clin Ultrasound. 1996 Jul-Aug;24(6):277-85
pubmed: 8792267
Neurogastroenterol Motil. 2001 Jun;13(3):179-85
pubmed: 11437980
Gastroenterology. 2012 Dec;143(6):1473-1481.e3
pubmed: 22982184
Clin Chem. 1998 May;44(5):991-1001
pubmed: 9590372
Regul Pept. 2003 Nov 15;116(1-3):21-5
pubmed: 14599711
AJR Am J Roentgenol. 1985 Nov;145(5):1009-11
pubmed: 3901703
Regul Pept. 2010 Aug 9;163(1-3):96-101
pubmed: 20580750
Curr Gastroenterol Rep. 2003 Aug;5(4):302-9
pubmed: 12864960
Peptides. 2000 Jan;21(1):73-80
pubmed: 10704722
World J Gastroenterol. 2010 May 7;16(17):2075-9
pubmed: 20440847
Scand J Gastroenterol. 2009;44(3):314-9
pubmed: 19005872
J Clin Endocrinol Metab. 2019 Jul 1;104(7):2463-2472
pubmed: 30137354
Gastroenterology. 2006 Jan;130(1):44-54
pubmed: 16401467
Am J Physiol Gastrointest Liver Physiol. 2010 Nov;299(5):G1038-44
pubmed: 20705903
Gut. 2009 Aug;58(8):1091-103
pubmed: 19240062
Int J Obes Relat Metab Disord. 2003 Apr;27(4):450-6
pubmed: 12664078
Front Endocrinol (Lausanne). 2017 Apr 13;8:47
pubmed: 28450850
Mol Metab. 2017 Mar 31;6(6):503-511
pubmed: 28580281
J Gen Physiol. 2002 Mar;119(3):251-73
pubmed: 11865021
Nat Med. 2006 Nov;12(11):1253-5
pubmed: 17072310
Scand J Gastroenterol. 2004 Apr;39(4):353-8
pubmed: 15125467
Gastroenterology. 1980 Jul;79(1):40-6
pubmed: 7380222

Auteurs

Nina L Hansen (NL)

Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.

Andreas Brønden (A)

Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.

Christina C Nexøe-Larsen (CC)

Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.

Alexander S Christensen (AS)

Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
Steno Diabetes Center Copenhagen, Gentofte, Denmark.

David P Sonne (DP)

Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.

Jens F Rehfeld (JF)

Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Nicolai J Wever Albretchsen (NJ)

Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Bolette Hartmann (B)

Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Tina Vilsbøll (T)

Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
Steno Diabetes Center Copenhagen, Gentofte, Denmark.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Jens J Holst (JJ)

Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Filip K Knop (FK)

Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
Steno Diabetes Center Copenhagen, Gentofte, Denmark.
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH